Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.33 |
| ▸ | GAA | P10253 | 7/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21863531 | 0.81 | MAPT (0.36) | MAPTGAAKDM4EALDH1A1HTT | |
| SCHEMBL12196940 | 0.72 | GAA (0.36) | MAPTGAAKDM4EALDH1A1HTT | |
| SCHEMBL16160353 | 0.67 | BRAF (0.39) | MAPTGAAKDM4EALDH1A1HTT | |
| SCHEMBL11892538 | 0.67 | GAA (0.39) | MAPTGAAKDM4EALDH1A1HTT | |
| SCHEMBL31153442 | 0.66 | MAPT (0.38) | MAPTGAAKDM4EALDH1A1HTT | |
| SCHEMBL15636218 | 0.64 | SRC (0.35) | — | |
| SCHEMBL8829295 | 0.63 | KDM4E (0.33) | MAPTGAAKDM4EALDH1A1HTT | |
| SCHEMBL21863289 | 0.61 | MAPT (0.40) | MAPTGAAKDM4EALDH1A1HTT | |
| SCHEMBL12146436 | 0.60 | BRAF (0.46) | MAPTGAAKDM4EALDH1A1HTT | |
| SCHEMBL13377438 | 0.60 | MAPT (0.39) | MAPTGAAKDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150250785-A1 | Tropomyosin-Related Kinase Inhibitors | PFIZER LIMITED (GB) | 2015-09-10 | — | — | US | disclosed |
| EP-2903986-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | Pfizer Limited (GB) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014053965-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2014-04-10 | — | — | WO | disclosed |
| US-20100076087-A1 | METHODS OF REDUCTION OF INTERPATIENT VARIABILITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076087-A1 | METHODS OF REDUCTION OF INTERPATIENT VARIABILITY | TPMT, GUSB, CYP2D6 | MAPT 3605/4885GAA 975/4885KDM4E 4077/4885 |
| US-20150250785-A1 | Tropomyosin-Related Kinase Inhibitors | MUSK, TPM3, TNNI3 | MAPT 687/4885GAA 3116/4885KDM4E 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.